USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; text-indent: 35.4pt; line-height: 200%; text-align: justify; mso-pagination: none; mso-layout-grid-align: none;"><span style="mso-ansi-language: EN-GB;" lang="EN-GB"><span styl...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2010-02-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/article/view/5582 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850283444720893952 |
|---|---|
| author | Claudio Ucciferri Katia Falasca Paola Mancino Eligio Pizzigallo Jacopo Vecchiet |
| author_facet | Claudio Ucciferri Katia Falasca Paola Mancino Eligio Pizzigallo Jacopo Vecchiet |
| author_sort | Claudio Ucciferri |
| collection | DOAJ |
| description | <p class="MsoNormal" style="margin: 0cm 0cm 0pt; text-indent: 35.4pt; line-height: 200%; text-align: justify; mso-pagination: none; mso-layout-grid-align: none;"><span style="mso-ansi-language: EN-GB;" lang="EN-GB"><span style="font-size: small;"><span style="font-family: Times New Roman;">Haematological abnormalities are common during combination antiviral therapy for chronic hepatitis C. Although dose reduction or discontinuation can easily treat these side effects, they can adversely affect the efficacy of combination antiviral therapy reducing the likelihood of a sustained viral response (SVR). To avoid potentially diminishing a patient’s chance of response, many physicians have begun using growth factors off-label to manage anaemia and neutropenia in hepatitis C. Haematopoietic growth factors are generally well tolerated and they may be useful for managing haematological side effects of anti-HCV therapy improving patients’ quality of life. To date, the role and benefit of these agents during anti-HCV therapy and their positive impact on SVR have not conclusively determined in the published studies. However, the possibility of a benefit to individual outpatients remains, and an individualized approach is recommended. This review explores the incidence, clinical significance, and management of anaemia, neutropenia and thrombocytopenia associated with combination therapy for HCV infection.</span></span></span></p> |
| format | Article |
| id | doaj-art-eb2471d05c4d4b53ba13dc43051e60d0 |
| institution | OA Journals |
| issn | 2035-3006 |
| language | English |
| publishDate | 2010-02-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-eb2471d05c4d4b53ba13dc43051e60d02025-08-20T01:47:47ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062010-02-0121e2010003e2010003USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITISClaudio UcciferriKatia FalascaPaola MancinoEligio PizzigalloJacopo Vecchiet<p class="MsoNormal" style="margin: 0cm 0cm 0pt; text-indent: 35.4pt; line-height: 200%; text-align: justify; mso-pagination: none; mso-layout-grid-align: none;"><span style="mso-ansi-language: EN-GB;" lang="EN-GB"><span style="font-size: small;"><span style="font-family: Times New Roman;">Haematological abnormalities are common during combination antiviral therapy for chronic hepatitis C. Although dose reduction or discontinuation can easily treat these side effects, they can adversely affect the efficacy of combination antiviral therapy reducing the likelihood of a sustained viral response (SVR). To avoid potentially diminishing a patient’s chance of response, many physicians have begun using growth factors off-label to manage anaemia and neutropenia in hepatitis C. Haematopoietic growth factors are generally well tolerated and they may be useful for managing haematological side effects of anti-HCV therapy improving patients’ quality of life. To date, the role and benefit of these agents during anti-HCV therapy and their positive impact on SVR have not conclusively determined in the published studies. However, the possibility of a benefit to individual outpatients remains, and an individualized approach is recommended. This review explores the incidence, clinical significance, and management of anaemia, neutropenia and thrombocytopenia associated with combination therapy for HCV infection.</span></span></span></p>http://www.mjhid.org/article/view/5582HepatitisThrombocytopeniaInterferon |
| spellingShingle | Claudio Ucciferri Katia Falasca Paola Mancino Eligio Pizzigallo Jacopo Vecchiet USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS Mediterranean Journal of Hematology and Infectious Diseases Hepatitis Thrombocytopenia Interferon |
| title | USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS |
| title_full | USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS |
| title_fullStr | USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS |
| title_full_unstemmed | USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS |
| title_short | USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS |
| title_sort | use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for hcv hepatitis |
| topic | Hepatitis Thrombocytopenia Interferon |
| url | http://www.mjhid.org/article/view/5582 |
| work_keys_str_mv | AT claudioucciferri useofhematopoieticgrowthfactorinthemanagementofhematologicalsideeffectsassociatedtoantiviraltreatmentforhcvhepatitis AT katiafalasca useofhematopoieticgrowthfactorinthemanagementofhematologicalsideeffectsassociatedtoantiviraltreatmentforhcvhepatitis AT paolamancino useofhematopoieticgrowthfactorinthemanagementofhematologicalsideeffectsassociatedtoantiviraltreatmentforhcvhepatitis AT eligiopizzigallo useofhematopoieticgrowthfactorinthemanagementofhematologicalsideeffectsassociatedtoantiviraltreatmentforhcvhepatitis AT jacopovecchiet useofhematopoieticgrowthfactorinthemanagementofhematologicalsideeffectsassociatedtoantiviraltreatmentforhcvhepatitis |